Back to results

Completed

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

NCT02993614

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Wilmington, Delaware, United States

+16 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2017-11-30
Enrollment: 99,999 participants
Sponsor: AstraZeneca

Locations (17)

Research SiteWilmington, Delaware, United States
Research SiteMelbourne, D1690r00015, Australia
Research SiteMississauga, D1690r00015, Canada
Research SiteGentofte Municipality, D1690r00015, Denmark
Research SiteEspoo, D1690r00015, Finland
Research SiteUlm, D1690r00015, Germany
Research SiteRaanana, D1690r00015, Israel
Research SiteRome, D1690r00015, Italy
Research SiteTokyo, D1690r00015, Japan
Research SiteOslo, D1690r00015, Norway
Research SitePorto, D1690r00015, Portugal
Research SiteSingapore, D1690r00015, Singapore
Research SiteSeoul, D1690r00015, South Korea
Research SiteMadrid, D1690r00015, Spain
Research SiteSödertälje, D1690r00015, Sweden
Research SiteTaipei, D1690r00015, Taiwan
Research SiteLuton, D1690r00015, United Kingdom

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors — TrialFind